Latest Breaking News On - Commercial arjun prasad - Page 1 : comparemela.com

Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.

Servier tibsovoServier pharmaceuticals head of commercial arjun prasadA servier pharmaceuticalsAgios pharmaceuticalsBristol myers squibbServier pharmaceuticalsPharmaceuticals headCommercial arjun prasadSagard healthcareWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciences